Study Summary
This study aims to evaluate the safety and efficacy of humanized Anti-CD19 Chimeric Antigen Receptor-T cell (CAR19T2 T cell) in children with refractory/relapsed B-cell acute lymphoblastic leukemia/lymphoma.
Want to learn more about this trial?
Request More InfoInterventions
CD19 CAR T-Cell(CAT19T2)BIOLOGICAL
Drug: Fludarabine， Administered intravenously Drug: Cyclophosphamide， Administered intravenously
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Guangdong Zhaotai Cell Bio-tech Co., LTD | Guangzhou | Guangdong | China |
| Zhujiang Hospital of Southern Medical University | Guanzhou | Guangdong | China |